Use of synthetic and biologic DMARDs during pregnancy

References

• Levy RA, de Jesús GR, de Jesús NR, et al. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev. 2016;15:955–963.
   PubMed Web of Science ®Google Scholar
• Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55:1693–1697.
   PubMed Web of Science ®Google Scholar
• Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol. 2017;10:661–669.
   PubMed Web of Science ®Google Scholar
• Skorpen CG, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Seow CH, Maxwell C, et al. The toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734–757.
   PubMed Web of Science ®Google Scholar
• van der Woude CJ, Ardizzone S, Bengston MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn’s Colitis. 2015;9:107–124.
   Google Scholar
• Wallace D, Gudsoorkar V, Weisman M, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–533.
   PubMed Web of Science ®Google Scholar
• Levy R, Vilela V, Cataldo M, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10:401–404.
   PubMed Web of Science ®Google Scholar
• Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476–485.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Houng D, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev.. 2005;4:111–115.
   PubMed Web of Science ®Google Scholar
• Moroni G, Doria A, Giglio E, et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun.. 2016;74:6–12.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev. 2015;14:498–502.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Branch DW, Levy RA, et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost.. 2016;115:285–290.
   PubMed Web of Science ®Google Scholar
• De CS, Botta A, Salvi S, et al. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? Autoimmun Rev. 2015;14:760–762.
   PubMed Web of Science ®Google Scholar
• Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to improve pregnancy outcome in women with antIphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome. Semin Thromb Hemost. 2017;43:562–571.
   PubMed Web of Science ®Google Scholar
• Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol. 2011;38:2504–2508.
   PubMed Web of Science ®Google Scholar
• Noviani M, Wasserman S, Clowse M. Breastfeeding in mothers with systemic lupus erythematosus. Lupus. 2016;25:973–979.
   PubMed Web of Science ®Google Scholar
• Polifka J, Friedman J. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240–261.
   PubMedGoogle Scholar
• Hazes J, Coulie P, Geenen V, et al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50:1955–1968.
   PubMed Web of Science ®Google Scholar
• Akbari M, Shah S, Velayos F, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15–22.
   PubMed Web of Science ®Google Scholar
• Alami Z, Agier M, Ahid S, et al. Pregnancy outcome following in utero exposure to azathioprine: a french comparative observational study. Therapie. 2018;73:199–207.
   PubMed Web of Science ®Google Scholar
• Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs. 2011;71:1973–1987.
   PubMed Web of Science ®Google Scholar
• Norgard B, Pedersen L, Christensen L, et al. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406–1413.
   PubMed Web of Science ®Google Scholar
• Viktil K, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol. 2012;41:196–201.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–789.
   PubMed Web of Science ®Google Scholar
• Østensen M, Forger F. How safe are anti-rheumatic drugs during pregnancy?. Curr Opin Pharmacol. 2013;13:470–475.
   PubMed Web of Science ®Google Scholar
• Mohamed-Ahmed O, Nelson-Piercy C, Bramham K, et al. Pregnancy outcomes in liver and cardiothoracic transplant recipients: a UK national cohort study. PLoS One. 2014;9:e89151.
   PubMed Web of Science ®Google Scholar
• Perales-Puchalt A, Vives JV, Montes JL, et al. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison. J Matern Fetal Neonatal Med. 2012;25:1363–1366.
   PubMed Web of Science ®Google Scholar
• Nulman I, Sgro M, Barrera M, et al. Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant. Paediatr Drugs. 2010;12:113–122.
   PubMedGoogle Scholar
• Reggia R, Bazzani C, Andreoli L, et al. The efficacy and safety of cyclosporin a in pregnant patients with systemic autoimmune diseases. Am J Reprod Immunol. 2016;75:654–660.
   PubMed Web of Science ®Google Scholar
• Zheng S, Easterling T, Hays K, et al. Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. Br J Clin Pharmacol. 2013;76:988–996.
   PubMed Web of Science ®Google Scholar
• Bramham K, Chusney G, Lee J, et al. Breastfeeding and tacrolimus: serial monitoring in breastfed and bottle-fed infants. Clin J Am Soc Nephrol. 2013;8:563–567.
   PubMed Web of Science ®Google Scholar
• Lannes G, Elias F, Cunha B, et al. Successful pregnancy after cyclophosphamide therapy for lupus nephritis. Arch Gynecol Obs. 2011;283(Suppl):61–65.
   PubMedGoogle Scholar
• Greenberg L, Tanaka K. Congenital anomalies probably induced by cyclophosphamide. JAMA. 1964;188:423–426.
   PubMed Web of Science ®Google Scholar
• Enns G, Roeder E, Chan R, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet. 1999;86:237–241.
   PubMed Web of Science ®Google Scholar
• Koseoglu HK, Yucel A, Kunefeci G, et al. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus. 2001;10:818–820.
   PubMed Web of Science ®Google Scholar
• Harris E. Antirheumatic drugs in pregnancy. Lupus. 2002;11:683–689.
   PubMed Web of Science ®Google Scholar
• Wiernik P, Duncan J. Cyclophosphamide in human milk. Lancet. 1971;1:912.
   PubMed Web of Science ®Google Scholar
• Hyoun S, Obican S, Scialli A. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94:187–207.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101–1110.
   PubMed Web of Science ®Google Scholar
• Thorne J, Nadarajah T, Moretti M, et al. Methotrexate use in a breastfeeding patient with rheumatoid arthritis. J Rheumatol. 2014;41:2332.
   PubMedGoogle Scholar
• Brent R. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001;63:106–112.
   PubMedGoogle Scholar
• Cassina M, Johnson D, Robinson L, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64:2085–2094.
   PubMed Web of Science ®Google Scholar
• Bérard A, Zhao J, Shui I, et al. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes. Ann Rheum Dis. 2018;77:500–509.
   PubMed Web of Science ®Google Scholar
• Ransom J. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995;17:681–684.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European network of teratology information services. Am J Med Genet. 2012;158:588–596.
   Google Scholar
• Merlob P, Stahl B, Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol. 2009;28:105–108.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. Expert Opin Drug Saf. 2014;13:1749–1762.
   PubMed Web of Science ®Google Scholar
• Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology (Oxford). 2010;49:2225–2227.
   PubMed Web of Science ®Google Scholar
• Murashima A, Watanabe N, Ozawa N. Etanercept during pregnancy and lactation in a patients with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009;68:1973–1974.
   Web of Science ®Google Scholar
• Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13(12):1699–1708.
   PubMed Web of Science ®Google Scholar
• Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the Macaque immune system. Am J Reprod Immunol. 2007;58:138–149.
   PubMed Web of Science ®Google Scholar
• Lau A, Clark M, Harrison D, et al. THU0153 pregnancy outcomes in women exposed to the tumor necrosis factr inhibitor, golimumab. Ann Rheum Dis. 2014;73:232–233.
   Web of Science ®Google Scholar
• Schreiber S. Certolizumab pegol for the treatment of Crohn’s disease. Therap Adv Gastroenterol. 2011;4:375–389.
   PubMedGoogle Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228–233.
   PubMed Web of Science ®Google Scholar
• Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70:1399–1407.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890–1896.
   PubMed Web of Science ®Google Scholar
• UCB (2018). CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S. [online]. cited 2018 Oct 20. Available from: https://www.ucb.com/stories-media/Press-Releases/article/CIMZIA-certolizumab-pegol-label-update-marks-major-advance-for-women-of-childbearing-age-with-chronic-inflammatory-disease-in-the-U-S
   Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug the. Arthritis Rheum. 2008;58:2968–2980.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–1523.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol. 2013;40:113–126.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid art. Ann Rheum Dis. 2014;73:69–74.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Goupille P, Moosavi S, et al. First experiences with pregnancies in RA patients (pts) receiving tocilizumab (TCZ) therapy. Arthritis Rheum. 2010;62(suppl):384.
   Google Scholar
• Østensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann NY Acad Sci. 2014;1317:32–38.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Sugitani M, Goto M, et al. Tocilizumab and pregnancy: four cases of pregnancy in young women with rheumatoid arthritis refractory to anti-TNF biologics with exposure to tocilizumab. Mod Rheumatol. 2016;26:672–675.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Watanabe O, Mochizuki M, et al. Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan. Mod Rheumatol. 2016;26:667–671.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Beck E, Rajwanshi R, et al. Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Sem Arthritis Rheum. 2016;46:238–245.
   PubMed Web of Science ®Google Scholar
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–2040.
   PubMed Web of Science ®Google Scholar
• Genentech. FDA approves Roche’s MabThera/Rituxan (rituximab) for pemphigus vulgaris [Online]. [cited 2018 Aug 24]. Available from: https://www.roche.com/investors/updates/inv-update-2018-06-08.htm.
   Google Scholar
• Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499–1506.
   PubMed Web of Science ®Google Scholar
• De Cock D, Birmingham L, Watson KD, et al. Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology (Oxford). 2017;56:663–665.
   PubMed Web of Science ®Google Scholar
• Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy. Neurol - Neuroimmunol Neuroinflammation. 2018;5:e453.
   PubMed Web of Science ®Google Scholar
• Ojeda-Uribe M, Afif N, Dahan E, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 2013;32:695–700.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar
• Nash P, Mease PJ, McInnes IB, et al. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20:1–11.
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz A, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open. 2017;3:e000592.
   PubMed Web of Science ®Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis. 2017;76:571–575.
   PubMed Web of Science ®Google Scholar
• Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018 Jun 21 Epub ahead of print. DOI:10.1111/bjd.16901.
   Web of Science ®Google Scholar
• Martin P, Sachs C, Imai N. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–363.
   PubMed Web of Science ®Google Scholar
• Kimball A, Goyal K, Langholff W. Pregnancy outcome in women with moderate to severe psoriasis: the PSOLAR experience. J Am Acad Dermatol. 2014;70(Suppl):AB179.
   Google Scholar
• Schaufelberger B, Horn E, Cather J. Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program. J Am Acad Dermatol. 2014;70(Suppl):AB178.
   Google Scholar
• Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and blood cord in a woman with Crohn’s disease treated until 33 weeks gestation. J Crohns Colitis. 2018;12:376–378.
   PubMed Web of Science ®Google Scholar
• Watson N, Wu K, Farr P, et al. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies. Br J Dermatol. 2018 Aug 13. doi:10.1111/bjd.17086.
   Google Scholar
• Galluzzo M, D’Adamio S, Bianchi L, et al. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatolog Treat. 2018 May 3:1–5 Epub ahead of print. DOI:10.1080/09546634.2018.1468066.
   Google Scholar
• Megna M, Villani A, Balato N, et al. Letter to the Editor submitted in response to “psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatol Treat. 2018:1–6. DOI:10.1080/09546634.2018.1508818. ahead of print.
   PubMedGoogle Scholar
• Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther 2017;42:234–236.
   Google Scholar
• Afsar B, Covic A, Ortiz A, et al. The Future of IL-1 targeting in kidney disease. Drugs [Internet]. 2018;1–11. Available from https://doi.org/10.1007/s40265-018-0942-2
   Google Scholar
• Baskar S, Klein AL, Zeft A. The use of IL-1 receptor antagonist (anakinra) in idiopathic recurrent pericarditis: a narrative review. Cardiol Res Pract. 2016;2016:1–6.
   Google Scholar
• Smith CJF, Chambers CD. Five successful pregnancies with antenatal anakinra exposure. Rheumatology (Oxford). 2018;57:1271–1275.
   PubMed Web of Science ®Google Scholar
• Youngstein T, Hoffmann P, Gül A, et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology (Oxford). 2017;56:2102–2108.
   PubMed Web of Science ®Google Scholar
• Chang Z, Spong CY, Jesus AA, et al. Brief report: anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes. Arthritis Rheumatol. 2014;66:3227–3232.
   PubMed Web of Science ®Google Scholar
• Ilgen U, Kucusahin O. Anakinra use during pregnancy: report of a case with Familial Mediterranean Fever and infertility. Eur J Rheumatol. 2017;4:66–67.
   PubMed Web of Science ®Google Scholar
• Toplak N, Blazina S, Avčin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018;12:1633–1643.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908–1919.
   PubMed Web of Science ®Google Scholar
• Sota J, Vitale A, Insalaco A, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37:2233–2240.
   PubMed Web of Science ®Google Scholar
• Egawa M, Imai K, Mori M, et al. Placental transfer of canakinumab in a patient with muckle-wells syndrome. J Clin Immunol. 2017;37:339–341.
   PubMed Web of Science ®Google Scholar
• Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol. 2011;71:639–641.
   PubMed Web of Science ®Google Scholar
• Autmizguine J, Cohen-Wolkowiez M, Ilowite N. Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2015;55:39–44.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Ozdogan H, Simon A, et al. OR14-002 Anti IL-1 therapies and pregnancy outcome. Pediatr Rheumatol. 2013;11(suppl. 1):A269.
   Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.
   PubMed Web of Science ®Google Scholar
• Auyeung-Kim D, Devalaraja M, Migone T. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod Toxicol. 2009;28:443–455.
   PubMed Web of Science ®Google Scholar
• Burmester G, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–460.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Xeljanz prescring information. [online]. cited 2018 Aug 22. Available from: http://labelingpfizer.com/ShowLabeling.aspx?id=959. 2014.
   Google Scholar
• Clowse M, Feldman S, Isaacs J, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39:755–762.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Dubinsky M, Su C, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;izy160. DOI:10.1093/ibd/izy160.
   Google Scholar
• Taylor P, Keystone E, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662.
   PubMed Web of Science ®Google Scholar
• Fridman J, Scherle P, Collins R. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298–5307.
   PubMed Web of Science ®Google Scholar
• Eli Lilly Co. Olumiant [package insert]. Indianapolis. 2018. cited 2018 Aug 22. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf.
   Google Scholar